AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10928373 — intervention group
Group type: COMPARATOR
Intervention: Norfloxacin (Salmonella diarrhea)
Number of subjects: 170
Study 10928373 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftibuten (Shigella diarrhea)
Number of subjects: 170
Study 10928373 — intervention group
Group type: COMPARATOR
Intervention: Norfloxacin (Shigella diarrhea)
Number of subjects: 170
Study 7747847 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 40
Study 7747847 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil
Number of subjects: 40
Study 2293074 — intervention group
Group type: EXPERIMENTAL
Intervention: methoxybutropate
Number of subjects: 30
Study 2293074 — intervention group
Group type: COMPARATOR
Intervention: bromeline
Number of subjects: 30
Study 6166363 — intervention group
Group type: EXPERIMENTAL
Intervention: bleomycin
Number of subjects: 202
Study 6166363 — intervention group
Group type: EXPERIMENTAL
Intervention: Baker's antifol
Number of subjects: 202
Study 6166363 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorodeoxyuridine plus arabinosyl cytosine
Number of subjects: 202
Study 6166363 — intervention group
Group type: EXPERIMENTAL
Intervention: tilorone
Number of subjects: 202
Study 6166363 — intervention group
Group type: EXPERIMENTAL
Intervention: CCNU
Number of subjects: 202
Study 6166363 — intervention group
Group type: EXPERIMENTAL
Intervention: streptozotocin
Number of subjects: 202
Study 30791963 — intervention group
Group type: EXPERIMENTAL
Intervention: MBT-DH
Number of subjects: 114
Study 30791963 — intervention group
Group type: COMPARATOR
Intervention: MBT-IOP
Number of subjects: 114
Study 30795889 — intervention group
Group type: EXPERIMENTAL
Intervention: LDR brachytherapy (I-125 seeds, preplanned)
Number of subjects: 60
Study 30795889 — intervention group
Group type: COMPARATOR
Intervention: HDR brachytherapy (27 Gy/2 fractions, intraoperative planning)
Number of subjects: 60
Study 30795889 — intervention group
Group type: EXPERIMENTAL
Intervention: LDR brachytherapy (peripheral DILs)
Number of subjects: 60
Study 30795889 — intervention group
Group type: EXPERIMENTAL
Intervention: LDR brachytherapy (central or anterior DILs)
Number of subjects: 60
Study 30795889 — intervention group
Group type: COMPARATOR
Intervention: HDR brachytherapy (peripheral DILs)
Number of subjects: 60
Study 30795889 — intervention group
Group type: COMPARATOR
Intervention: HDR brachytherapy (central or anterior DILs)
Number of subjects: 60
Study 30795889 — intervention group
Group type: COMPARATOR
Intervention: Comparison of DIL D90 between modalities
Number of subjects: 60
Study 27939836 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin 22.5 mg given as 24-week depot injections
Number of subjects: 58
Study 27939836 — intervention group
Group type: COMPARATOR
Intervention: Subcapsular orchiectomy
Number of subjects: 58
Study 25883316 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsidies to the majority of the landless poor
Number of subjects: 380
Study 25883316 — intervention group
Group type: COMPARATOR
Intervention: Community motivation alone
Number of subjects: 380
Study 25883316 — intervention group
Group type: COMPARATOR
Intervention: Supply-side market access intervention
Number of subjects: 380
Study 24335969 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 158
Study 24335969 — intervention group
Group type: COMPARATOR
Intervention: Control (no spironolactone)
Number of subjects: 158
Study 22539173 — intervention group
Group type: EXPERIMENTAL
Intervention: Talking Diabetes programme
Number of subjects: 693
Study 22539173 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 693
Study 19375088 — intervention group
Group type: EXPERIMENTAL
Intervention: Short loop tail stent
Number of subjects: 236
Study 19375088 — intervention group
Group type: EXPERIMENTAL
Intervention: Long loop tail stent
Number of subjects: 236
Study 19375088 — intervention group
Group type: EXPERIMENTAL
Intervention: Percuflex Plus stent
Number of subjects: 236
Study 19375088 — intervention group
Group type: EXPERIMENTAL
Intervention: Polaris stent
Number of subjects: 236
Study 19375088 — intervention group
Group type: COMPARATOR
Intervention: All stents
Number of subjects: 236
Study 17560293 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/day) in subjects with high ADMA
Number of subjects: 98
Study 17560293 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin plus L-arginine (3 g/day) in subjects with high ADMA
Number of subjects: 98
Study 17560293 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/day) in subjects with low ADMA
Number of subjects: 98
Study 17560293 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin plus L-arginine (3 g/day) in subjects with low ADMA
Number of subjects: 98
Study 17560293 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (3 g/day) alone in both groups
Number of subjects: 98
Study 17560293 — intervention group
Group type: COMPARATOR
Intervention: Endothelium-independent vasodilation
Number of subjects: 98
Study 15457277 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (125-250 mg) and unfractionated heparin (5,000 units bolus followed by infusion titrated to maintain activated partial thromboplastin time of 50-75 s); Q-wave MI patients also received thrombolytic therapy (1.5 million units of streptokinase)
Number of subjects: 92
Study 15457277 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and unfractionated heparin
Number of subjects: 92
Study 15457277 — intervention group
Group type: COMPARATOR
Intervention: Control group (15 patients with stable angina)
Number of subjects: 92
Study 11354590 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 423
Study 9879697 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI evidence of inflammatory lesions in the conus/epiconus region of the spinal cord
Number of subjects: 12
Study 9879697 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI axial images of the conus-epiconus region
Number of subjects: 12
Study 9879697 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical and electrophysiological evaluation
Number of subjects: 12
Study 8021760 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 63
Study 8021760 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 63
Study 31935529 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT), maximum 26 sessions, up to six months
Number of subjects: 63
Study 31935529 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 63
Study 30121618 — intervention group
Group type: EXPERIMENTAL
Intervention: One-session treatment (OST)
Number of subjects: 286
Study 30121618 — intervention group
Group type: COMPARATOR
Intervention: Multisession cognitive-behavioural therapy (CBT)
Number of subjects: 286
Study 27544612 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 5mg
Number of subjects: 190
Study 27544612 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10mg
Number of subjects: 190
Study 27544612 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20mg
Number of subjects: 190
Study 27544612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study 25917214 — intervention group
Group type: EXPERIMENTAL
Intervention: Lattice System Physician's Global Assessment (LS-PGA)
Number of subjects: 445
Study 25917214 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoriasis Area and Severity Index (PASI)
Number of subjects: 445
Study 25917214 — intervention group
Group type: EXPERIMENTAL
Intervention: Static Physician's Global Assessment (sPGA)
Number of subjects: 445
Study 25917214 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life (QoL) related to physicians' assessments of body surface area involved with psoriasis (iBSA)
Number of subjects: 445
Study 24044803 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone tangential field (TF) intensity modulated radiotherapy (IMRT)
Number of subjects: 100
Study 20868373 — intervention group
Group type: EXPERIMENTAL
Intervention: Incredible Years preventive program plus a shortened six-week version of the SPOKES literacy program
Number of subjects: 174
Study 20868373 — intervention group
Group type: COMPARATOR
Intervention: Usual community services
Number of subjects: 174
Study 19887866 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine monotherapy (64% of patients, median starting dose 1,070 mg/m² b.i.d.)
Number of subjects: 846
Study 19887866 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine combination chemotherapy (36% of patients, median starting dose 987 mg/m² b.i.d.)
Number of subjects: 846
Study 17396057 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation (48 participants)
Number of subjects: 138
Study 14766712 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion at a starting rate of 6-9 microg kg(‐1) h(‐1) for up to 72 h, with additional propofol (0.5 mg kg(‐1) h(‐1) if required)
Number of subjects: 40
Study 11688664 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifocal contact lenses
Number of subjects: 21
Study 11688664 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifocal contact lenses
Number of subjects: 21
Study 11688664 — intervention group
Group type: COMPARATOR
Intervention: Monofocal contact lenses (controls)
Number of subjects: 21
Study 9387174 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival anesthesia
Number of subjects: 60
Study 9387174 — intervention group
Group type: COMPARATOR
Intervention: Peribulbar anesthesia
Number of subjects: 60
Study 9387174 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 60
Study 8183520 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 0.1% eye drops
Number of subjects: 0
Study 8183520 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 0.03% eye drops
Number of subjects: 0
Study 8183520 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic flurbiprofen (added to topical drugs)
Number of subjects: 0
Study 8183520 — intervention group
Group type: COMPARATOR
Intervention: Control group (no eye drops)
Number of subjects: 0
Study 3370077 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (5 mg)
Number of subjects: 6
Study 3370077 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (5 mg)
Number of subjects: 6
Study 3370077 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 30893430 — intervention group
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA solution for injection (ASI) 50 U
Number of subjects: 185
Study 30893430 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study 29991757 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellomics approach combining optogenetics and Brainbow technologies for high-throughput behavioral analysis.
Number of subjects: 0
Study 27765756 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 10 mg/kg + gemcitabine/cisplatin (arm A)
Number of subjects: 24
Study 27765756 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab + pemetrexed/cisplatin (arm B)
Number of subjects: 24
Study 27765756 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab + paclitaxel/carboplatin/bevacizumab (arm C)
Number of subjects: 24
Study 27765756 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab + docetaxel (arm D)
Number of subjects: 24
Study 25903058 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompt group (INT) received three daily screen-based prompts for 12 weeks.
Number of subjects: 38
Study 25903058 — intervention group
Group type: COMPARATOR
Intervention: Non-prompt group (CON) received only one instruction about the benefits of HAWDs.
Number of subjects: 38
Study 25903058 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompt group (INT) for concentration and neuromuscular performance.
Number of subjects: 38
Study 23063263 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver-directed therapy (including hepatic resection, thermal ablation, intra-arterial therapy)
Number of subjects: 0
Study 23063263 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin analogues, sunitinib, and everolimus
Number of subjects: 0
Study 23063263 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial therapy (IAT)
Number of subjects: 0
Study 20962287 — intervention group
Group type: EXPERIMENTAL
Intervention: Hallucinations with insight
Number of subjects: 89
Study 20962287 — intervention group
Group type: EXPERIMENTAL
Intervention: Hallucinations without insight
Number of subjects: 89
Study 20962287 — intervention group
Group type: COMPARATOR
Intervention: Sleep fragmentation
Number of subjects: 89
Study 20962287 — intervention group
Group type: COMPARATOR
Intervention: Vivid dreams/nightmares
Number of subjects: 89
Study 20962287 — intervention group
Group type: COMPARATOR
Intervention: Acting out dreams
Number of subjects: 89
Study 18226435 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study 18226435 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin with dexamethasone or chemotherapy
Number of subjects: 0
Study 15691342 — intervention group
Group type: EXPERIMENTAL
Intervention: Gingivectomy (GV)
Number of subjects: 15
Study 15691342 — intervention group
Group type: COMPARATOR
Intervention: Open-flap debridement (OFD)
Number of subjects: 15
Study 12534402 — intervention group
Group type: EXPERIMENTAL
Intervention: onercept 11.7 mg three times weekly for 2 weeks
Number of subjects: 12
Study 12534402 — intervention group
Group type: EXPERIMENTAL
Intervention: onercept 50 mg three times weekly for 2 weeks
Number of subjects: 12
Study 11208371 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligation of the main trunk of the inferior thyroid artery (Group 1)
Number of subjects: 37
Study 11208371 — intervention group
Group type: COMPARATOR
Intervention: Ligation of only the branches of the inferior thyroid artery (Group 2)
Number of subjects: 37
Study 9275422 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 25 mg twice with 12 hours apart (Group 1)
Number of subjects: 300
Study 9275422 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of mifepristone 25 mg (Group 2)
Number of subjects: 300
Study 9275422 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 25 mg and anordrin 7.5 mg given once (Group 3)
Number of subjects: 300
Study 1903336 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide acetate
Number of subjects: 22
Study 1903336 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 22
Study 6675183 — intervention group
Group type: EXPERIMENTAL
Intervention: End-to-side jejunoileal bypass (ES)
Number of subjects: 21
Study 6675183 — intervention group
Group type: COMPARATOR
Intervention: End-to-end jejunoileal bypass (EE)
Number of subjects: 21
Study 30589533 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg of MDMA
Number of subjects: 124
Study 30589533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 30241302 — intervention group
Group type: EXPERIMENTAL
Intervention: CGA-added beverage daily for 16 weeks
Number of subjects: 38
Study 30241302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 30241302 — intervention group
Group type: EXPERIMENTAL
Intervention: CGA-added beverage
Number of subjects: 38
Study 26621909 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistently elevated C-reactive protein (CRP) level (≥ 5 mg/L at both baseline and 24 weeks after ART initiation)
Number of subjects: 205
Study 26621909 — intervention group
Group type: COMPARATOR
Intervention: Persistently low CRP level
Number of subjects: 205
Study 24445737 — intervention group
Group type: EXPERIMENTAL
Intervention: UVA irradiation of the skin with two standard erythemal doses
Number of subjects: 24
Study 24445737 — intervention group
Group type: EXPERIMENTAL
Intervention: UVA irradiation of the forearm
Number of subjects: 24
Study 24445737 — intervention group
Group type: COMPARATOR
Intervention: Acute dietary intervention aimed at modulating systemic nitrate availability
Number of subjects: 24
Study 22236919 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid (INH)
Number of subjects: 0
Study 22236919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19410576 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon plasma coagulation (APC)
Number of subjects: 21
Study 19410576 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure (control)
Number of subjects: 21
Study 17995496 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg daily for 48 weeks)
Number of subjects: 572
Study 17995496 — intervention group
Group type: COMPARATOR
Intervention: E2/NETA (1 mg 17beta estradiol plus 0.5 mg norethisterone acetate daily for 48 weeks)
Number of subjects: 572
Study 15522363 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 454
Study 15522363 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 454
Study 11498060 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy
Number of subjects: 0
Study 11498060 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft surgery
Number of subjects: 0
Study 11498060 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy (low ejection fraction subgroup)
Number of subjects: 0
Study 11498060 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft surgery (low ejection fraction subgroup)
Number of subjects: 0
Study 9467540 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.3 micrograms/kg.day recombinant human GH (rhGH)
Number of subjects: 6
Study 9467540 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 micrograms/kg.day recombinant human GH (rhGH)
Number of subjects: 6
Study 9467540 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 6
Study 7890448 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher frequency response options presented prior to lower frequency response options
Number of subjects: 350
Study 7890448 — intervention group
Group type: COMPARATOR
Intervention: Quantitativeness of response options and location of items within the questionnaire
Number of subjects: 350
Study 3063047 — intervention group
Group type: EXPERIMENTAL
Intervention: Alinidine (0.6 mg.kg‐1 i.v.)
Number of subjects: 24
Study 3063047 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (0.035 mg.kg‐1 i.v.)
Number of subjects: 24
Study 29898585 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill training, stretching, respiratory, and proprioceptive exercises (TreSPE study)
Number of subjects: 53
Study 29898585 — intervention group
Group type: COMPARATOR
Intervention: CMT Neuropathy Score, 6MWT, 10MWT, Berg Balance Scale (BBS), Short Physical Performance Battery (SPPB), SF36, Walk12
Number of subjects: 53
Study 29049194 — intervention group
Group type: EXPERIMENTAL
Intervention: Action observation therapy (8 weeks, 6 times per week, 20 minutes per session)
Number of subjects: 53
Study 29049194 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation treatments
Number of subjects: 53
Study 27115508 — intervention group
Group type: EXPERIMENTAL
Intervention: Real tDCS (1.5 mA, cathodal over bilateral FPT for 20 min)
Number of subjects: 20
Study 27115508 — intervention group
Group type: COMPARATOR
Intervention: Control tDCS stimulation (turning off the stimulation after 30 s)
Number of subjects: 20
Study 25099476 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 91
Study 25099476 — intervention group
Group type: COMPARATOR
Intervention: Biolimus-eluting stent (BES)
Number of subjects: 91
Study 22161999 — intervention group
Group type: EXPERIMENTAL
Intervention: General approach to scan GWAS SNP data for gene-level and gene-set analyses.
Number of subjects: 0
Study 22161999 — intervention group
Group type: EXPERIMENTAL
Intervention: Application of methods to two different GWAS.
Number of subjects: 0
Study 19393840 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release quetiapine fumarate (IR)
Number of subjects: 63
Study 19393840 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release quetiapine fumarate (XR)
Number of subjects: 63
Study 17905960 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous Compression Plate (PCCP)
Number of subjects: 104
Study 17905960 — intervention group
Group type: COMPARATOR
Intervention: Compression Hip Screw (CHS)
Number of subjects: 104
Study 17905960 — intervention group
Group type: EXPERIMENTAL
Intervention: PCCP
Number of subjects: 104
Study 15309258 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexpanthenol nasal spray (5%)
Number of subjects: 20
Study 15309258 — intervention group
Group type: COMPARATOR
Intervention: Dexpanthenol nasal ointment (5%)
Number of subjects: 20
Study 11746320 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean function regression model
Number of subjects: 0
Study 11746320 — intervention group
Group type: COMPARATOR
Intervention: Random effects models
Number of subjects: 0
Study 10574380 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimodal (audio-visual) speech stimulation
Number of subjects: 0
Study 10574380 — intervention group
Group type: COMPARATOR
Intervention: Unimodal (auditory and visual) components
Number of subjects: 0
Study 7883933 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide (50:50 mixture with oxygen)
Number of subjects: 30
Study 7883933 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular sedation (meperidine and promethazine)
Number of subjects: 30
Study 7883933 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide
Number of subjects: 30
Study 7883933 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular sedation
Number of subjects: 30
Study 2204333 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous interpleural infusion of bupivacaine (n = 8)
Number of subjects: 16
Study 2204333 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion of papaveretum (n = 8)
Number of subjects: 16
Study 723506 — intervention group
Group type: EXPERIMENTAL
Intervention: Circuit Weight Training (CWT)
Number of subjects: 41
Study 723506 — intervention group
Group type: EXPERIMENTAL
Intervention: Running (RN)
Number of subjects: 41
Study 723506 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 41
Study 31613424 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure on SP6 point
Number of subjects: 60
Study 31416506 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel combined with aspirin
Number of subjects: 77
Study 31416506 — intervention group
Group type: COMPARATOR
Intervention: Low-molecular-weight heparin and aspirin
Number of subjects: 77